Browsing Pathways
Showing 391 -
400 of 605359 pathways
SMPDB ID | Pathway Name and Description | Pathway Class | Chemical Compounds | Proteins |
---|---|---|---|---|
SMP0142830View Pathway |
Thiethylperazine Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0126476View Pathway |
Thiethylperazine Dopamine Antagonist Action PathwayThiethylperazine is in the class of the piperazine - phenothiazines which are a class of first generation antipsychotic medications. Phenothiazines are generally dopamine receptor antagonists. Thiethylperazine' s antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Thiethylperazine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. It is a sedating antihistamine used as an antiemetic agent for the control of nausea and vomiting associated with surgical procedures.
|
Drug Action
|
|
|
SMP0060742View Pathway |
Thiazinamium H1-Antihistamine ActionThiazinamium is a first-generation phenothiazine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.
|
Drug Action
|
||
SMP0143574View Pathway |
Thiamylal Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0142623View Pathway |
Thiamine Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0143173View Pathway |
Thiabendazole Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0142737View Pathway |
Theophylline Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0062624View Pathway |
Thenyldiamine H1-Antihistamine ActionThenyldiamine is an ethylenediamine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.
|
Drug Action
|
||
SMP0145284View Pathway |
Thenyldiamine Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0062894View Pathway |
Thenalidine H1-Antihistamine ActionThenalidine is a piperidine H1-antihistamine that was withdrawn from Canadian, US, and UK markets in 1963 due to concerns involving neutropenia (DB04826). H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.
|
Drug Action
|
Showing 391 -
400 of 4295 pathways